CorMedix Inc. said the New York Stock Exchange accepted its plan to regain compliance with its listing requirements.

The Brisbane, Calif.-based company had said in June that it received a noncompliance notice from the NYSE American.

The biopharmaceutical company had reported a stockholders' equity of $800,000, lower than a minimum of $2 million as required by NYSE.

CorMedix, which submitted its plan on July 16, has until Dec. 16, 2019 to regain compliance.